Even if further studies must be undertaken to elucidate how the genetic variants of PRKG1 might influence cardiovascular diseases, in homozygote PRKG1 polymorphisms carriers, RLX could be ineffective in the treatment of hypertension and hypertensive heart diseases, suggesting an accurate evaluation of RLX effect in clinical setting. Here, PRKG1 is linked to hypertensive heart disease.